Coherus Oncology
CHRS
196 hedge funds and large institutions have $1.51B invested in Coherus Oncology in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 68 increasing their positions, 71 reducing their positions, and 27 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
41% more call options, than puts
Call options by funds: $1.62M | Put options by funds: $1.14M
0.29% more ownership
Funds ownership: 120.25% → 120.54% (+0.29%)
4% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 71
4% less capital invested
Capital invested by funds: $1.58B → $1.51B (-$69.6M)
2% less funds holding
Funds holding: 201 → 196 (-5)
11% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$29M |
| 2 |
PA
Perceptive Advisors
New York
|
+$18.4M |
| 3 |
ACB
Aristotle Capital Boston
Boston,
Massachusetts
|
+$15.1M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$9.89M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$6.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$22.3M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$18.1M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$14.9M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$12.6M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$8.95M |
CHRS Hedge Fund Activity: Q4 2020 in Review
196 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2020, worth a combined $1.51B — down 4.4% from $1.58B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CHRS and 24 opened new positions — a net loss of 3 holders — while 71 trimmed existing stakes and 68 added.
The largest buyer was Vaughan Nelson Investment Management, opening a new position worth an estimated $29M. The largest seller was Bellevue Group, cutting an estimated $22.3M.
- 196 institutional investors held Coherus Oncology (CHRS) as of Q4 2020, down from 201 in Q3 2020.
- Funds reported $1.51B of Coherus Oncology stock for Q4 2020, down 4.4% quarter-over-quarter.
- 24 funds opened new Coherus Oncology positions in Q4 2020 and 27 closed out, a net change of -3 holders.
- The largest Coherus Oncology buyer in Q4 2020 was Vaughan Nelson Investment Management, an estimated $29M added.
- The largest Coherus Oncology seller in Q4 2020 was Bellevue Group, an estimated $22.3M sold.
Based on aggregated 13F filings for Q4 2020.